Lupin has launched Digital Asthma Educator platform. The platform guides asthma patients on the correct technique of using inhalers. The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.
According to estimates, India has nearly 35 million people living with asthma, including children. While there is no cure for Asthma, it is manageable with proper treatment, vigilance, drug adherence and regular medical checks, thus enabling patients to lead a normal life. Studies have revealed that incorrect use of inhalers often inhibits effective treatment of chronic respiratory ailments, leading to poor clinical control and eventually poor patient health outcome. Hence, it is important for patients to learn correct inhalation technique for better management of the respiratory ailment.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1913.05 |
| Dr. Reddys Labs. | 1368.75 |
| Cipla | 1471.25 |
| Zydus Lifesciences | 1148.05 |
| Lupin | 2492.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: